Irinotecan HCl-trihydraat Hospira 20 mg/ml concentraat voor oplossing voor infusie オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

irinotecan hcl-trihydraat hospira 20 mg/ml concentraat voor oplossing voor infusie

hospira benelux bvba - irinotecanhydrochloride 3-water samenstelling overeenkomend met ; irinotecan - concentraat voor oplossing voor infusie - melkzuur (d,l,+- vorm) (e 270) ; natriumhydroxide (e 524) ; sorbitol (d-)(e 420) ; stikstof (head space) (e 941) ; water voor injectie ; zoutzuur (e 507), - irinotecan

Lapatinib PharOS 250 mg, filmomhulde tabletten オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

lapatinib pharos 250 mg, filmomhulde tabletten

lapatinibditosilaat 1-water 405 mg/stuk samenstelling overeenkomend met ; lapatinib 250 mg/stuk - filmomhulde tablet - cellulose, microkristallijn (e 460(i)) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171), cellulose, microkristallijn (e 460) ; hypromellose, type 2910 (3 - 15 mpa.s) (e 464) ; ijzeroxide geel (e 172) ; macrogol 400 ; magnesiumstearaat (e 470b) ; natriumzetmeelglycolaat ; polysorbaat 80 (e 433) ; povidon k 30 (e 1201) ; titaandioxide (e 171)

Irinotecan HCl-3-water CF 20 mg/ml concentraat voor oplossing voor infusie オランダ - オランダ語 - CBG-MEB (College ter Beoordeling van Geneesmiddelen)

irinotecan hcl-3-water cf 20 mg/ml concentraat voor oplossing voor infusie

centrafarm b.v. nieuwe donk 3 4879 ac etten leur - irinotecanhydrochloride 3-water samenstelling overeenkomend met ; irinotecan - concentraat voor oplossing voor infusie - melkzuur (d,l,+- vorm) (e 270) ; natriumhydroxide (e 524) ; sorbitol (d-)(e 420) ; water voor injectie, - irinotecan

Irinotecan Accord 20 mg/ml inf. opl. (conc.) i.v. flac. ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan accord 20 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - irinotecanhydrochloridetrihydraat 20 mg/ml - concentraat voor oplossing voor infusie - 20 mg/ml - irinotecanhydrochloridetrihydraat 20 mg/ml - topoisomerase 1 (top1) inhibitors

Irinotecan Accord 20 mg/ml inf. opl. (conc.) i.v. flac. ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan accord 20 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - irinotecanhydrochloridetrihydraat 20 mg/ml - concentraat voor oplossing voor infusie - 20 mg/ml - irinotecanhydrochloridetrihydraat 20 mg/ml - topoisomerase 1 (top1) inhibitors

Irinotecan Accord 20 mg/ml inf. opl. (conc.) i.v. flac. ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan accord 20 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - irinotecanhydrochloridetrihydraat 20 mg/ml - concentraat voor oplossing voor infusie - 20 mg/ml - irinotecanhydrochloridetrihydraat 20 mg/ml - topoisomerase 1 (top1) inhibitors

Irinotecan Accord 20 mg/ml inf. opl. (conc.) i.v. flac. ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan accord 20 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - irinotecanhydrochloridetrihydraat 20 mg/ml - concentraat voor oplossing voor infusie - 20 mg/ml - irinotecanhydrochloridetrihydraat 20 mg/ml - topoisomerase 1 (top1) inhibitors

Irinotecan Accord 20 mg/ml inf. opl. (conc.) i.v. flac. ベルギー - オランダ語 - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

irinotecan accord 20 mg/ml inf. opl. (conc.) i.v. flac.

accord healthcare b.v. - irinotecanhydrochloridetrihydraat 20 mg/ml - concentraat voor oplossing voor infusie - 20 mg/ml - irinotecanhydrochloridetrihydraat 20 mg/ml - topoisomerase 1 (top1) inhibitors

Herwenda 欧州連合 - オランダ語 - EMA (European Medicines Agency)

herwenda

sandoz gmbh - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastische middelen - treatment of metastatic and early breast cancer and metastatic gastric cancer (mgc).

Aybintio 欧州連合 - オランダ語 - EMA (European Medicines Agency)

aybintio

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastische middelen - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. zie rubriek 5 voor meer informatie over de status van humane epidermale groeifactorreceptor 2 (her2). 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. raadpleeg sectie 5 voor meer informatie over her2-status. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).